«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2025 04

Page:

525-547

Research Field:

Publishing date:

Info

Title:

Research progress of immunotherapy for lung cancer

Author(s):

ZHANG Xu; CAO Wanxin; LI Xiaoxue; YANG Hong; LI Wan; CHI Xiangyin; DU Guanhua; WANG Jinhua

Beijing Key Laboratory of Drug Target Research and New Drug Screening,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China.

Keywords:

immunotherapy; immune checkpoint; CAR-T; CAR-NK; oncolytic virus; vaccine

PACS:

R734.2

DOI:

10.3969/j.issn.1672-4992.2025.04.001

Abstract:

Lung cancer is one of the most malignant cancers in the world,with the highest incidence and mortality rates among all types of cancer.Non-small cell lung cancer is the common subtype of lung cancer.Current drug treatments for lung cancer mainly includs chemotherapy,targeted therapy and immunotherapy.Chemotherapy have limited benefit and significant side effects.In recent years,immunotherapy for lung cancer has made great progress,with broad prospects and good results.This article reviews the latest progress in immunotherapy of lung cancer,including immune checkpoint inhibitor therapy,CAR-T therapy,CAR-NK therapy,oncolytic virus therapy and lung cancer vaccines,in order to provide insights for clinical and basic research on lung cancer immunotherapy.

References:

£Û1£Ý SCHWENDENWEIN A,MEGYESFALVI Z,BARANY N,et al.Molecular profiles of small cell lung cancer subtypes:Therapeutic implications £ÛJ£Ý.Mol Ther-Oncolytics,2021,20:470-483.
£Û2£Ý XIONG J,HE L,CHAI X,et al.YTHDF1 boosts the lactate accumulation to potentiate cervical cancer cells immune escape £ÛJ£Ý.Cell Death Dis,2024,15(11):843.
£Û3£Ý RECK M,RODR¦PGUEZ-ABREU D,ROBINSON AG,et al.Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer £ÛJ£Ý.N Engl J Med,2016,375(19):1823-1833.
£Û4£Ý HERBST RS,BAAS P,KIM DW,et al.Pembrolizumab versus docetaxel for previously treated,PD-L1-positive,advanced non-small-cell lung cancer (KEYNOTE-010):a randomised controlled trial £ÛJ£Ý.Lancet,2016,387(10027):1540-1550.
£Û5£Ý BRAHMER J,RECKAMP KL,BAAS P,et al.Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer £ÛJ£Ý.N Engl J Med,2015,373(2):123-135.
£Û6£Ý BORGHAEI H,PAZ-ARES L,HORN L,et al.Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer £ÛJ£Ý.N Engl J Med,2015,373(17):1627-1639.
£Û7£Ý BORGHAEI H,GETTINGER S,VOKES EE,et al.Five-year outcomes from the randomized,phase III trials CheckMate 017 and 057:Nivolumab versus docetaxel in previously treated non-small-cell lung cancer £ÛJ£Ý.J Clin Oncol,2021,39(7):723-733.
£Û8£Ý RITTMEYER A,BARLESI F,WATERKAMP D,et al.Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK):a phase 3,open-label,multicentre randomised controlled trial £ÛJ£Ý.Lancet,2017,389(10066):255-265.
£Û9£Ý ANTONIA SJ,VILLEGAS A,DANIEL D,et al.Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer £ÛJ£Ý.N Engl J Med,2017,377(20):1919-1929.
£Û10£Ý BRAHMER JR,LEE JS,CIULEANU TE,et al.Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in CheckMate 227 £ÛJ£Ý.J Clin Oncol,2023,41(6):1200-1212.
£Û11£Ý CHO BC,ABREU DR,HUSSEIN M,et al.Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE):primary and follow-up analyses of a randomised,double-blind,phase 2 study £ÛJ£Ý.Lancet Oncol,2022,23(6):781-792.
£Û12£Ý CAI L,LI Y,TAN J,et al.Targeting LAG-3,TIM-3,and TIGIT for cancer immunotherapy £ÛJ£Ý.J Hematol Oncol,2023,16(1):101.
£Û13£Ý CHENG W,KANG K,ZHAO A,et al.Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer £ÛJ£Ý.J Hematol Oncol,2024,17(1):54.
£Û14£Ý ZHAO L,CHENG S,FAN L,et al.TIM-3:An update on immunotherapy £ÛJ£Ý.Int Immunopharmacol,2021,99:107933.
£Û15£Ý CHAUVIN JM,ZAROUR HM.TIGIT in cancer immunotherapy £ÛJ£Ý.J Immunother Cancer,2020,8(2):e000957.
£Û16£Ý LIN X,KANG K,CHEN P,et al.Regulatory mechanisms of PD-1/PD-L1 in cancers £ÛJ£Ý.Mol Cancer,2024,23(1):108.
£Û17£Ý GARON EB,HELLMANN MD,RIZVI NA,et al.Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab:results from the phase I KEYNOTE-001 study £ÛJ£Ý.J Clin Oncol,2019,37(28):2518-2527.
£Û18£Ý ZHOU C,HUANG D,FAN Y,et al.Tislelizumab versus docetaxel in patients with previously treated advanced NSCLC (RATIONALE-303):A phase 3,open-label,randomized controlled trial £ÛJ£Ý.J Thorac Oncol,2023,18(1):93-105.
£Û19£Ý ROWSHANRAVAN B,HALLIDAY N,SANSOM DM.CTLA-4:a moving target in immunotherapy £ÛJ£Ý.Blood,2018,131(1):58-67.
£Û20£Ý LIU Y,ZHENG P.Preserving the CTLA-4 checkpoint for safer and more effective cancer immunotherapy £ÛJ£Ý.Trends Pharmacol Sci,2020,41(1):4-12.
£Û21£Ý AGGARWAL V,WORKMAN CJ,VIGNALI DAA.LAG-3 as the third checkpoint inhibitor £ÛJ£Ý.Nat Immunol,2023,24(9):1415-1422.
£Û22£Ý HE Y,YU H,ROZEBOOM L,et al.LAG-3 protein expression in non-small cell lung cancer and its relationship with PD-1/PD-L1 and tumor-infiltrating lymphocytes £ÛJ£Ý.J Thorac Oncol,2017,12(5):814-823.
£Û23£Ý KOYAMA S,AKBAY EA,LI YY,et al.Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints £ÛJ£Ý.Nat Commun,2016,7:10501.
£Û24£Ý GOMES DE MORAIS AL,CERD¦B S,DE MIGUEL M.New checkpoint inhibitors on the road:targeting TIM-3 in solid tumors £ÛJ£Ý.Curr Oncol Rep,2022,24(5):651-658.
£Û25£Ý CHU X,TIAN W,WANG Z,et al.Co-inhibition of TIGIT and PD-1/PD-L1 in cancer immunotherapy:mechanisms and clinical trials £ÛJ£Ý.Mol Cancer,2023,22(1):93.
£Û26£Ý L¦INA H,GREILLIER L,CROPET C,et al.Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ¡Ý70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY):a randomised,open-label,phase 3 study £ÛJ£Ý.The Lancet Respiratory Medicine,2024,12(10):775-787.
£Û27£Ý HELLMANN MD,PAZ-ARES L,BERNABE CARO R,et al.Nivolumab plus £ÛJ£Ý.N Engl J Med,2019,381(21):2020-2031.
£Û28£Ý PAZ-ARES L,CIULEANU TE,COBO M,et al.First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA):an international,randomised,open-label,phase 3 trial £ÛJ£Ý.Lancet Oncol,2021,22(2):198-211.
£Û29£Ý BAHCE I,DICKHOFF C,SCHNEIDERS FL,et al.Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer:the INCREASE study £ÛJ£Ý.J Immunother Cancer,2024,12(9):e009799.
£Û30£Ý LIN CC,CURIGLIANO G,SANTORO A,et al.Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy:a phase 2 multicentre study £ÛJ£Ý.BMJ Open,2024,14(8):e079132.
£Û31£Ý ÕÔ†´,°×èë,ÍõÖ¾½Ü,µÈ.Ö×Áö΢»·¾³ÓëÃâÒßÖÎÁÆÄÍÒ©µÄ¹Øϵ¼°Ó¦¶Ô£ÛJ£Ý.ÏÖ´úÖ×Áöҽѧ,2020,28(22):3985-3989.ZHAO Z,BAI H,WANG ZJ,et al.The relationship between the tumor microenvironment and immune therapy resistance and corresponding countermeasures £ÛJ£Ý.Modern Oncology,2020,28(22):3985-3089.
£Û32£Ý PROVENCIO M,NADAL E,INSA A,et al.Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM):5-year clinical outcomes from a multicentre,single-arm,phase 2 trial £ÛJ£Ý.Lancet Oncol,2024,25(11):1453-1464.
£Û33£Ý MOLINA-ALEJANDRE M,PEREA F,CALVO V,et al.Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer £ÛJ£Ý.J Immunother Cancer,2024,12(10):e009762.
£Û34£Ý SE B,EYSA A,KARIM N.Clinical insights:five-year follow-up of KEYNOTE-189 trial outcomes and more £ÛJ£Ý.Transl Lung Cancer Res,2024,13(8):2095-2097.
£Û35£Ý SOCINSKI MA,JOTTE RM,CAPPUZZO F,et al.Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC £ÛJ£Ý.N Engl J Med,2018,378(24):2288-2301.
£Û36£Ý WEST H,MCCLEOD M,HUSSEIN M,et al.Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130):a multicentre,randomised,open-label,phase 3 trial £ÛJ£Ý.Lancet Oncol,2019,20(7):924-937.
£Û37£Ý JOTTE R,CAPPUZZO F,VYNNYCHENKO I,et al.Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131):Results from a randomized phase III trial £ÛJ£Ý.J Thorac Oncol,2020,15(8):1351-1360.
£Û38£Ý RIZVI NA,CHO BC,REINMUTH N,et al.Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer:the MYSTIC phase 3 randomized clinical trial £ÛJ£Ý.JAMA Oncol,2020,6(5):661-674.
£Û39£Ý PAZ-ARES L,LUFT A,VICENTE D,et al.Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer £ÛJ£Ý.N Engl J Med,2018,379(21):2040-2051.
£Û40£Ý PAZ-ARES L,DVORKIN M,CHEN Y,et al.Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN):a randomised,controlled,open-label,phase 3 trial £ÛJ£Ý.Lancet,2019,394(10212):1929-1939.
£Û41£Ý REN S,HE J,FANG Y,et al.Camrelizumab plus apatinib in treatment-naive patients with advanced nonsquamous NSCLC:A multicenter,open-label,single-arm,phase 2 trial £ÛJ£Ý.JTO Clin Res Rep,2022,3(5):100312.
£Û42£Ý GRAY JE,SCHENKER M,NAHIT SENDUR MA,et al.The phase 3 KEYLYNK-006 study of pembrolizumab plus olaparib versus pembrolizumab plus pemetrexed as maintenance therapy for metastatic nonsquamous non-small-cell lung cancer £ÛJ£Ý.J Thorac Oncol,2024,19(11):1469-1580.
£Û43£Ý CHANG ZL,CHEN YY.CARs:Synthetic immunoreceptors for cancer therapy and beyond £ÛJ£Ý.Trends Mol Med,2017,23(5):430-450.
£Û44£Ý BANNAS P,HAMBACH J,KOCH-NOLTE F.Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics £ÛJ£Ý.Front Immunol,2017,8:1603.
£Û45£Ý WU W,ZHOU Q,MASUBUCHI T,et al.Multiple signaling roles of CD3¦Å and its application in CAR-T cell therapy £ÛJ£Ý.Cell,2020,182(4):855-871.e823.
£Û46£Ý CAPPELL KM,KOCHENDERFER JN.A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains £ÛJ£Ý.Nat Rev Clin Oncol,2021,18(11):715-727.
£Û47£Ý CHMIELEWSKI M,ABKEN H.TRUCKs:the fourth generation of CARs£ÛJ£Ý.Expert Opin Biol Th,2015,15(8):1145-1154.
£Û48£Ý TOKAREW N,OGONEK J,ENDRES S,et al.Teaching an old dog new tricks:next-generation CAR T cells £ÛJ£Ý.Brit J Cancer,2019,120(1):26-37.
£Û49£Ý ZUBAIR T,BANDYOPADHYAY D.Small molecule EGFR inhibitors as anti-cancer agents:discovery,mechanisms of action,and opportunities £ÛJ£Ý.Int J Mol Sci,2023,24(3):2651.
£Û50£Ý ZHANG Z,JIANG J,WU XD,et al.Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy £ÛJ£Ý.Front Med-Prc,2019,13(1):57-68.
£Û51£Ý LI H,HUANG Y,JIANG DQ,et al.Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice £ÛJ£Ý.Cell Death Dis,2018,9(2):177.
£Û52£Ý WHILDING LM,HALIM L,DRAPER B,et al.CAR T-cells targeting the integrin ¦Áv¦Â6 and co-expressing the chemokine receptor CXCR2 demonstrate enhanced homing and efficacy against several solid malignancies £ÛJ£Ý.Cancers (Basel),2019,11(5):674.
£Û53£Ý LI GC,GUO JT,ZHENG YF,et al.CXCR5 guides migration and tumor eradication of anti-EGFR chimeric antigen receptor T cells £ÛJ£Ý.Mol Ther-Oncolytics,2021,22:507-517.
£Û54£Ý YEO D,CASTELLETTI L,VAN ZANDWIJK N,et al.Hitting the Bull¡¯s-eye:mesothelin¡¯s role as a biomarker and therapeutic target for malignant pleural mesothelioma £ÛJ£Ý.Cancers,2021,13(16):3932.
£Û55£Ý DING J,GUYETTE S,SCHRAND B,et al.Mesothelin-targeting T cells bearing a novel T cell receptor fusion construct (TRuC) exhibit potent antitumor efficacy against solid tumors £ÛJ£Ý.Oncoimmunology,2023,12(1):2182058.
£Û56£Ý ZHAO R,CHENG L,JIANG Z,et al.DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells £ÛJ£Ý.Oncoimmunology,2019,8(1):e1509173.
£Û57£Ý YE L,LOU YQ,LU LM,et al.Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors £ÛJ£Ý.Exp Ther Med,2019,17(1):739-747.
£Û58£Ý CHEN W,ZHANG Z,ZHANG S,et al.MUC1:Structure,function,and clinic application in epithelial cancers £ÛJ£Ý.International Journal of Molecular Sciences,2021,22(12):6567.
£Û59£Ý BOUILLEZ A,ADEEGBE D,JIN C,et al.MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer £ÛJ£Ý.Oncoimmunology,2017,6(9):e1338998.
£Û60£Ý ZHOU R,YAZDANIFAR M,ROY LD,et al.CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth £ÛJ£Ý.Front Immunol,2019,10:1149.
£Û61£Ý XIE G,DONG H,LIANG Y,et al.CAR-NK cells:A promising cellular immunotherapy for cancer £ÛJ£Ý.EBioMedicine,2020,59:102975.
£Û62£Ý LIU MT,HUANG WS,GUO YJ,et al.CAR NK-92 cells targeting DLL3 kill effectively small cell lung cancer cells in vitro and in vivo £ÛJ£Ý.J Leukocyte Biol,2022,112(4):901-911.
£Û63£Ý YANG S,CAO B,ZHOU G,et al.Targeting B7-H3 immune checkpoint with chimeric antigen receptor-engineered natural killer cells exhibits potent cytotoxicity against non-small cell lung cancer £ÛJ£Ý.Front Pharmacol,2020,11:1089.
£Û64£Ý PENG Y,ZHANG W,CHEN Y,et al.Engineering c-Met-CAR NK-92 cells as a promising therapeutic candidate for lung adenocarcinoma £ÛJ£Ý.Pharmacol Res,2023,188:106656.
£Û65£Ý CHAURASIYA S,CHEN NG,WARNER SG.Oncolytic virotherapy versus cancer stem cells:a review of approaches and mechanisms £ÛJ£Ý.Cancers,2018,10(4):124.
£Û66£Ý WILLMON C,HARRINGTON K,KOTTKE T,et al.Cell carriers for oncolytic viruses:Fed Ex for cancer therapy £ÛJ£Ý.Mol Ther,2009,17(10):1667-1676.
£Û67£Ý EVERTS A,BERGEMAN M,MCFADDEN G,et al.Simultaneous tumor and stroma targeting by oncolytic viruses £ÛJ£Ý.Biomedicines,2020,8(11):474.
£Û68£Ý RAHMAN MM,MCFADDEN G.Oncolytic viruses:Newest frontier for cancer immunotherapy £ÛJ£Ý.Cancers,2021,13(21):5452.
£Û69£Ý NIA GE,NIKPAYAM E,FARROKHI M,et al.Advances in cell-based delivery of oncolytic viruses as therapy for lung cancer£ÛJ£Ý.Mol Ther Oncol,2024,32(3):1667.
£Û70£Ý SALAUDDIN M,SAHA S,HOSSAIN MG,et al.Clinical application of adenovirus (AdV):A comprehensive review £ÛJ£Ý.Viruses-Basel,2024,16(7):1094.
£Û71£Ý LI TY,FANG JB,CHU JH,et al.In vivo and in vitro inhibition of SCLC by combining dual cancer-specific recombinant adenovirus with Etoposide £ÛJ£Ý.J Cancer Res Clin,2022,148(5):1073-1085.
£Û72£Ý AJAM-HOSSEINI M,AKHOONDI F,DOROUDIAN M.Nano based-oncolytic viruses for cancer therapy £ÛJ£Ý.Critical Reviews in Oncology/Hematology,2023,185:103980.
£Û73£Ý DOROUDIAN M,ZANGANEH S,ABBASGHOLINEJAD E,et al.Nanomedicine in lung cancer immunotherapy £ÛJ£Ý.Front Bioeng Biotechnol,2023,11:1144653.
£Û74£Ý XU L,SUN H,LEMOINE NR,et al.Oncolytic vaccinia virus and cancer immunotherapy £ÛJ£Ý.Front Immunol,2023,14:1324744.
£Û75£Ý SHI ZR,LIU B,HUANG CD,et al.An oncolytic vaccinia virus armed with anti-human-PD-1 antibody and anti-human-4-1BB antibody double genes for cancer-targeted therapy £ÛJ£Ý.Biochem Bioph Res Co,2021,559:176-182.
£Û76£Ý SUN F,GUO ZS,GREGORY AD,et al.Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer £ÛJ£Ý.J Immunother Cancer,2020,8(1):e000294.
£Û77£Ý TENESACA S,VASQUEZ M,ALVAREZ M,et al.Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors £ÛJ£Ý.J Immunother Cancer,2021,9(7):e001587.
£Û78£Ý BREITBACH CJ,BURKE J,JONKER D,et al.Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans £ÛJ£Ý.Nature,2011,477(7362):99-102.
£Û79£Ý RAMLAU R,QUOIX E,ROLSKI J,et al.A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer £ÛJ£Ý.J Thorac Oncol,2008,3(7):735-744.
£Û80£Ý M¦aLLER L,BERKELEY R,BARR T,et al.Past,present and future of oncolytic reovirus £ÛJ£Ý.Cancers,2020,12(11):3219.
£Û81£Ý HOTANI T,MIZUGUCHI H,SAKURAI F.Systemically administered reovirus-induced downregulation of hypoxia inducible factor-1¦Á in subcutaneous tumors £ÛJ£Ý.Mol Ther-Oncolytics,2019,12:162-172.
£Û82£Ý SEYED-KHORRAMI SM,SOLEIMANJAHI H,SOUDI S,et al.MSCs loaded with oncolytic reovirus:migration and in vivo virus delivery potential for evaluating anti-cancer effect in tumor-bearing C57BL/6 mice £ÛJ£Ý.Cancer Cell Int,2021,21(1):244.
£Û83£Ý BRADBURY PA,MORRIS DG,NICHOLAS G,et al.Canadian Cancer Trials Group (CCTG) IND211:A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy £ÛJ£Ý.Lung Cancer,2018,120:142-148.
£Û84£Ý GONG J,SACHDEV E,MITA AC,et al.Clinical development of reovirus for cancer therapy:An oncolytic virus with immune-mediated antitumor activity £ÛJ£Ý.World J Methodol,2016,6(1):25-42.
£Û85£Ý HARARI A,GRACIOTTI M,BASSANI-STERNBERG M,et al.Antitumour dendritic cell vaccination in a priming and boosting approach £ÛJ£Ý.Nat Rev Drug Discov,2020,19(9):635-652.
£Û86£Ý MORSE MA,GWIN WR,MITCHELL DA.Vaccine therapies for cancer:then and now £ÛJ£Ý.Target Oncol,2021,16(2):121-152.
£Û87£Ý SELLARS MC,WU CJ,FRITSCH EF.Review cancer vaccines:Building a bridge over troubled waters £ÛJ£Ý.Cell,2022,185(15):2770-2788.
£Û88£Ý RUHLAND MK,ROBERTS EW,CAI E,et al.Visualizing synaptic transfer of tumor antigens among dendritic cells £ÛJ£Ý.Cancer Cell,2020,37(6):786.
£Û89£Ý DILLMAN RO,NISTOR GI,KEIRSTEAD HS.Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines £ÛJ£Ý.Hum Vaccin Immunother,2023,19(1):2198467.
£Û90£Ý NEMUNAITIS J,STERMAN D,JABLONS D,et al.Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer £ÛJ£Ý.J Natl Cancer I,2004,96(4):326-331.
£Û91£Ý GOLLARD R,ARANA B,KALTENBRUN E,et al.Durable response to maintenance treatment comprised of viagenpumatucel-L,nivolumab,ramucirumab,and docetaxel in a PD-L1-low advanced-stage non-small-cell lung cancer:a case report £ÛJ£Ý.Case Rep Oncol,2023,16(1):431-437.
£Û92£Ý GIACCONE G,BAZHENOVA LA,NEMUNAITIS J,et al.A phase III study of belagenpumatucel-L,an allogeneic tumour cell vaccine,as maintenance therapy for non-small cell lung cancer £ÛJ£Ý.Eur J Cancer,2015,51(16):2321-2329.
£Û93£Ý BALAN S,SAXENA M,BHARDWAJ N.Dendritic cell subsets and locations £ÛJ£Ý.Int Rev Cel Mol Bio,2019,348:1-68.
£Û94£Ý DING Z,LI Q,ZHANG R,et al.Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer £ÛJ£Ý.Signal Transduct Target Ther,2021,6(1):26.
£Û95£Ý ZHAO Y,QIAO G,WANG X,et al.Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients:a prospective patients¡¯ preference-based study (PPPS)£ÛJ£Ý.Clin Transl Oncol,2019,21(6):721-728.
£Û96£Ý CHIAPPORI AA,WILLIAMS CC,GRAY JE,et al.Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer £ÛJ£Ý.Cancer Immunology,Immunotherapy,2019,68(3):517-527.
£Û97£Ý LOPES A,VANDERMEULEN G,PR¦IAT V.Cancer DNA vaccines:current preclinical and clinical developments and future perspectives £ÛJ£Ý.Journal of Experimental & Clinical Cancer Research,2019,38(1):146.
£Û98£Ý ADDEO A,FRIEDLAENDER A,GIOVANNETTI E,et al.A new generation of vaccines in the age of immunotherapy £ÛJ£Ý.Curr Oncol Rep,2021,23(12):137.
£Û99£Ý ZHU T,HAN J,YANG L,et al.Immune microenvironment in osteosarcoma:components,therapeutic strategies and clinical applications £ÛJ£Ý.Front Immunol,2022,13:907550.
£Û100£Ý GAMAT-HUBER M,JEON D,JOHNSON LE,et al.Treatment combinations with DNA vaccines for the treatment of metastatic castration-resistant prostate cancer (mCRPC)£ÛJ£Ý.Cancers,2020,12(10):2831.
£Û101£Ý MIAO L,ZHANG Y,HUANG L.mRNA vaccine for cancer immunotherapy £ÛJ£Ý.Mol Cancer,2021,20(1):41.
£Û102£Ý DUAN LJ,WANG Q,ZHANG C,et al.Potentialities and challenges of mRNA vaccine in cancer immunotherapy £ÛJ£Ý.Front Immunol,2022,13:923647.
£Û103£Ý VISHWESHWARAIAH YL,DOKHOLYAN NV.mRNA vaccines for cancer immunotherapy £ÛJ£Ý.Front Immunol,2022,13:1029069.
£Û104£Ý PAPACHRISTOFILOU A,HIPP MM,KLINKHARDT U,et al.Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy,BI1361849 (CV9202),combined with local radiation treatment in patients with stage IV non-small cell lung cancer £ÛJ£Ý.J Immunother Cancer,2019,7(1):38.
£Û105£Ý SEBASTIAN M,SCHR¦ZDER A,SCHEEL B,et al.A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer £ÛJ£Ý.Cancer Immunol Immun,2019,68(5):799-812.
£Û106£Ý PATEL MR,BAUER TM,JIMENO A,et al.A phase I study of mRNA-2752,a lipid nanoparticle encapsulating mRNAs encoding human OX40L,IL-23,and IL-36¦Ã,for intratumoral (iTu) injection alone and in combination with durvalumab £ÛJ£Ý.Journal of Clinical Oncology,2020,38(15):3092.
£Û107£Ý SU S,CHEN FJ,XU MY,et al.Recent advances in neoantigen vaccines for treating non-small cell lung cancer £ÛJ£Ý.Thorac Cancer,2023,14(34):3361-3368.
£Û108£Ý MCCANN K,VON WITZLEBEN A,THOMAS J,et al.Targeting the tumor mutanome for personalized vaccination in a TMB low non-small cell lung cancer £ÛJ£Ý.J Immunother Cancer,2022,10(3):e003821.
£Û109£Ý OTT PA,HU-LIESKOVAN S,CHMIELOWSKI B,et al.A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma,non-small cell lung cancer,or bladder cancer £ÛJ£Ý.Cell,2020,183(2):347-362.e324.
£Û110£Ý AWAD MM,GOVINDAN R,BALOGH KN,et al.Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer £ÛJ£Ý.Cancer Cell,2022,40(9):1010-1026.e1011.
£Û111£Ý BRAITEH F,LORUSSO P,BALMANOUKIAN A,et al.Abstract CT169:A phase Ia study to evaluate RO7198457,an individualized Neoantigen Specific immunoTherapy (iNeST),in patients with locally advanced or metastatic solid tumors £ÛJ£Ý.Cancer Research,2020,80(16):169.
£Û112£Ý LOPEZ JS,CAMIDGE R,IAFOLLA M,et al.Abstract CT301:A phase Ib study to evaluate RO7198457,an individualized Neoantigen Specific immunoTherapy (iNeST),in combination with atezolizumab in patients with locally advanced or metastatic solid tumors £ÛJ£Ý.Cancer Res,2020,80(16):301.
£Û113£Ý PALMER CD,RAPPAPORT AR,DAVIS MJ,et al.Individualized,heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors:phase 1 trial interim results £ÛJ£Ý.Nature Medicine,2022,28(8):1619-1629.
£Û114£Ý GAINOR JF,PATEL MR,WEBER J,et al.1530 T-cell responses to individualized neoantigen therapy (INT) mRNA-4157 (V940) as monotherapy or in combination with pembrolizumab £ÛJ£Ý.J Immunother Cancer,2023,11(2):1754.

Memo

Memo:

Öйúҽѧ¿ÆѧԺ´´Ð¹¤³Ì»ù½ð(±àºÅ£º2021-I2M-1-029£¬2023-I2M-2-006£©£»¹ú¼ÒÍâ¹úר¼ÒÏîÄ¿£¨±àºÅ£ºG2023194008L£©

Common functions

Last Update: 1900-01-01